CORT

Corcept Therapeutics' stock price has experienced significant fluctuations in the past six months. Starting at $34.80 at the beginning of 2026, it increased by 50.2% to $52.28 as of May 9, 2026, but over the last 12 months, its price fell by 25.56%. A major decline occurred on December 31, 2025, when the FDA issued a Complete Response Letter (CRL) for relacorilant, leading to a 50.4% single-day stock price collapse. Corcept reported its Q1 2026 earnings on April 30, 2026, missing revenue and EPS expectations, but raised its full-year revenue guidance for 2026 and announced positive two-year overall survival data from its Phase 2 study of dazucorilant in ALS.